Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

NCT00479856 | Terminated Phase 2 Results

• 1 other identifier: EGF108916
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 28

Brief Summary

This study will evaluate the safety and efficacy of lapatinib in combination with chemotherapy (capecitabine, docetaxel, nab-paclitaxel) in subjects with ErbB2-overexpressing breast cancer whose disease has progressed during or within 12 months after completion of trastuzumab-containing therapy in the neoadjuvant or adjuvant setting.

Conditions

Relapsed Breast Cancer; Neoplasms, Breast

Keywords

ErbB1; ErbB2; GW572016; lapatinib; Relapsed breast cancer; dual tyrosine kinase inhibitor; MBC; EGFR; Her-2/neu; FISH amplification

Outcome Measures

Primary Outcomes (1)

• Overall Tumor Response

  Overall tumor response is defined as the percentage of participants with a confirmed complete or partial tumor response per Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is defined as the disappearance of all target lesions. CR could only be declared if all target and non-target lesions had disappeared. Partial response (PR) is defined as a decrease of 30% or greater in the sum of the longest diameter of target lesions.

  from start of treatment and every 6 weeks (wks) until Wk 12, then every 12 wks thereafter through the end of treatment (~95 wks; dependent on when participant discontinued study therapy due to disease progression, death, adverse event, of other reason)

Secondary Outcomes (5)

• Clinical Benefit (CB)

  from start of treatment and every 6 weeks (wks) until Wk 12, then every 12 wks thereafter through the end of treatment (~95 weeks; dependent on when participant discontinued study therapy due to disease progression, death, adverse event, or other reason)

• Duration of Response

  time from first documented evidence of CR or PR until the first documented sign of disease progression or death (approximately 95 weeks)

• Time to Response (TTR)

  start of treatment until first documented evidence of CR or PR (approximately 95 weeks)

• Progression-free Survival

  from start of treatment and every 6 weeks (wks) until Wk 12, then every 12 wks thereafter through the end of treatment (~95 weeks); dependent on when participant discontinued study therapy due to disease progression, death, adverse event, or other reason)

• Number of Participants With the Indicated Serious Adverse Events and Adverse Events

  Baseline through End of Treatment, or discontinuation of study therapy (approximately 95 weeks); from the first dose of lapatinib until 5 days after the last dose of lapatinib

Study Arms (1)

Lapatinib plus Chemotherapy

EXPERIMENTAL

Lapatinib is administered in combination with one of the following chemotherapies based on the discretion of the investigator : capecitabine, docetaxel or nab-paclitaxel.

Drug: Lapatinib; Drug: Capecitabine; Drug: Docetaxel; Drug: nab-Paclitaxel

Interventions

Lapatinib DRUG

Small molecule tyrosine kinase inhibitor

Lapatinib plus Chemotherapy

Capecitabine DRUG

Chemotherapy

Lapatinib plus Chemotherapy

Docetaxel DRUG

Chemotherapy

Lapatinib plus Chemotherapy

nab-Paclitaxel DRUG

Chemotherapy

Lapatinib plus Chemotherapy

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed informed consent.
• Histologically/cytologically confirmed breast cancer;
• If the disease is restricted to a solitary lesion, the neoplastic nature of the lesion must be confirmed by cytology or histology.
• Measurable lesion(s) according to RECIST (Response Evaluation Criteria in Solid Tumors) \[Therasse, 2000\].
• Documented amplification of the ErbB2 gene by fluorescence in situ hybridization (FISH) or documented overexpression of the ErbB2 protein by 3+ IHC in primary or metastatic tumor tissue.
• Subjects must have relapsed breast cancer where the disease progressed during or ≤ 12 months after completion of trastuzumab-containing therapy in the neoadjuvant or adjuvant setting.
• Note: Progression is defined using RECIST criteria, that is, either the appearance of new lesions or a \>=20% increase in the sum of longest diameter (LD).
• Subjects must not have received prior anti-cancer therapy for metastatic breast cancer (MBC). Subjects who received prior antihormonal agents combined with trastuzumab for the treatment of disease which first presented as ER positive MBC and recurred while receiving trastuzumab or ≤ 3 months after completing this therapy are eligible.
• Subjects with stable central nervous system (CNS) metastases as confirmed by computerized tomography (CT)/magnetic resonance imaging (MRI) are allowed. Treatment with prophylactic anticonvulsants is permitted, unless listed within the Prohibited Medications.
• Subjects must have a baseline cardiac ejection fraction (LVEF) ³50% measured by echocardiogram (ECHO) (or multigated acquisition (MUGA) scan if an ECHO cannot be performed). The same modality used at baseline must be used for repeat assessment throughout study. Only subjects with controlled or asymptomatic angina or arrhythmias are eligible.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 2.
• Subjects must have archived tumor tissue from the initial diagnosis available for analysis. If tissue from the initial diagnosis is not available, then tissue must be obtained from a recurrent or metastatic site prior to initiating study treatment.
• Female ≥18 years.
• Subject must have adequate organ function as defined in Table 1.
• Table 1: Baseline Laboratory Values for Adequate Organ Function.

You may not qualify if:

• Pregnant or lactating females.
• Women of childbearing potential who do not practice approved contraceptive methods (for example, intrauterine device \[IUD\], birth control pills, or barrier device) beginning 2 weeks before the first dose of investigational product and for 28 days after the final dose of investigational product.
• History of other malignancy. However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.
• Concurrent therapy given to treat cancer (chemotherapy, radiation therapy, immunotherapy, biologic therapy, anti-hormonal therapy) while taking study medication.
• Unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior cancer treatment.
• Malabsorption syndrome or resection of the stomach or small bowel significantly affecting gastrointestinal function.
• Have current active haptic or biliary disease (with excpetion of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment).
• Concurrent disease or condition that, in the opinion of the physician, would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety (for example, uncontrolled infection, or any psychiatric condition prohibiting understanding or rendering of informed consent).
• Concurrent treatment with an investigational agent or participation in another clinical trial involving investigational agents for anti-cancer therapy.
• Bisphosphonates may not be initiated after the first dose of study medication.
• Considered by the Investigator to have a life expectancy less than 3 months.
• Not able to swallow or retain oral medication.
• The subject with a known unmanageable hypersensitivity reaction or idiosyncrasy to drugs chemically related to lapatinib or excipients and those related to capecitabine, docetaxel, nab paclitaxel or their excipients.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (28)

GSK Investigational Site

Hot Springs, Arkansas, 71913, United States

Location

GSK Investigational Site

Anaheim, California, 92801, United States

Location

GSK Investigational Site

Burbank, California, 91505, United States

Location

GSK Investigational Site

Highland, California, 92346, United States

Location

GSK Investigational Site

Long Beach, California, 90806, United States

Location

GSK Investigational Site

Sacramento, California, 95819, United States

Location

GSK Investigational Site

Washington D.C., District of Columbia, 20007, United States

Location

GSK Investigational Site

Fort Lauderdale, Florida, 33328, United States

Location

GSK Investigational Site

Hollywood, Florida, 33021, United States

Location

GSK Investigational Site

Orlando, Florida, 32806, United States

Location

GSK Investigational Site

Atlanta, Georgia, 30341, United States

Location

GSK Investigational Site

Lawrenceville, Georgia, 30045, United States

Location

GSK Investigational Site

Zion, Illinois, 60099, United States

Location

GSK Investigational Site

Indianapolis, Indiana, 46227, United States

Location

GSK Investigational Site

Metairie, Louisiana, 70006, United States

Location

GSK Investigational Site

New Orleans, Louisiana, 70112, United States

Location

GSK Investigational Site

Baltimore, Maryland, 21237, United States

Location

GSK Investigational Site

Minneapolis, Minnesota, 55426, United States

Location

GSK Investigational Site

Tupelo, Mississippi, 38801, United States

Location

GSK Investigational Site

Voorhees Township, New Jersey, 08043, United States

Location

GSK Investigational Site

Albuquerque, New Mexico, 87131-0001, United States

Location

GSK Investigational Site

New York, New York, 10016, United States

Location

GSK Investigational Site

Sumter, South Carolina, 29150, United States

Location

GSK Investigational Site

Austin, Texas, 78705, United States

Location

GSK Investigational Site

San Antonio, Texas, 78229, United States

Location

GSK Investigational Site

Ogden, Utah, 84403, United States

Location

GSK Investigational Site

Abingdon, Virginia, 24211, United States

Location

GSK Investigational Site

Fairfax, Virginia, 22031, United States

Location

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Lapatinib; Capecitabine; Docetaxel; 130-nm albumin-bound paclitaxel

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Quinazolines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Fluorouracil; Uracil; Pyrimidinones; Deoxyribonucleosides; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides; Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes

Results Point of Contact

• Title: GSK Response Center
• Organization: GlaxoSmithKline

866-435-7343

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 25, 2007
• First Posted: May 28, 2007
• Study Start: November 1, 2007
• Primary Completion: September 1, 2009
• Study Completion: March 1, 2010
• Last Updated: June 5, 2012
• Results First Posted: June 2, 2010

Record last verified: 2011-06

Locations

US (28)